Physician profile
Amir C Patel
NPI 1265685200
$137,034.06
in general payments reported to CMS, 2019-2025
9 companies · $82K in 2025
The $82K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $503 · 2020: $1,768 · 2021: $2,613 · 2022: $12K · 2023: $19K · 2024: $20K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $96K · Travel and Lodging: $16K · Consulting Fee: $4,200 · Food and Beverage: $4,067.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $96,187.00 |
| Travel and Lodging | $15,936.86 |
| Consulting Fee | $4,200.00 |
| Food and Beverage | $4,066.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $59,038.14 | 2019-2025 | |
| Janssen Biotech, INC. | $58,905.10 | 2024-2025 | Tremfya, Stelara |
| E.R. Squibb & Sons, L.L.C. | $14,296.38 | 2023-2024 | Zeposia |
| Celgene Corporation | $3,228.63 | 2022-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $1,187.99 | 2019-2022 | |
| Ardelyx, INC. | $127.82 | 2024 | Ibsrela |
| Pfizer INC. | $125.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.